| abstract |
The current application relates to nitrogen-containing fused ring compounds shown by the general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as a CRTH2 agonist, wherein X1, X2, X3, X4, X5 , W, X, Y, L1, L2, L3, A, B are as defined in the description; The current application also relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, the use of the compounds for the manufacture of a medicament for the treatment and prevention of diseases related to the activity of CRTH2 . (see Formula). |